ENDOCRINE TUMOURS: Approach to the patient with advanced differentiated thyroid cancer
- 1 January 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in Acta Endocrinologica
- Vol. 166 (1) , 5-11
- https://doi.org/10.1530/eje-11-0631
Abstract
Patients with advanced thyroid cancer may benefit froml-thyroxine treatment at doses that suppress serum TSH level, local treatment interventions, and radioiodine therapy. In those patients who are refractory to radioiodine therapy and in whom progressive disease has been documented, the efficacy of cytotoxic chemotherapy is poor. Encouraging results have been obtained with the use of kinase inhibitors that should be offered as first-line treatment, preferably in the context of a prospective trial.Keywords
This publication has 42 references indexed in Scilit:
- Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging CorrelationClinical Cancer Research, 2010
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium studyThe Lancet Oncology, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature, 2010
- Clinical Trials for Progressive Differentiated Thyroid Cancer: Patient Selection, Study Design, and Recent AdvancesThyroid®, 2009
- The Successful Use of Sorafenib to Treat Pediatric Papillary Thyroid CarcinomaThyroid®, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Postoperative External Beam Radiotherapy for Differentiated Thyroid Cancer: Outcomes and Morbidity With Conformal TreatmentInternational Journal of Radiation Oncology*Biology*Physics, 2008
- New therapeutic approaches for metastatic thyroid carcinomaThe Lancet Oncology, 2007
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000